Literature DB >> 6750176

Is captopril effective in primary pulmonary hypertension?

T Kokubu, Y Kazatani, M Hamada, K Matsuzaki, T Ito, K Nishimura, T Ochi, F Daimon, T Joh.   

Abstract

Several vasodilating agents have been used for the treatment of primary pulmonary hypertension (PPH). However, no effective therapy is currently available for this distressful disease. We tried to use an angiotensin-I converting enzyme inhibitor, captopril, for one woman suffering from PPH. Her initial treatment with furosemide, digoxin and spironolactone had shown little effect. Further administration of captopril improved her clinical condition from NYHA IV to II and made it possible to treat her at our out-clinic. No adverse effect has been found. We would like to appreciate captopril as one of the effective drugs in the treatment of PPH.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6750176     DOI: 10.1253/jcj.46.1095

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  7 in total

1.  Management of primary pulmonary hypertension.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1985-01

Review 2.  Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

3.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

4.  Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis.

Authors:  Bradley A Maron; William M Oldham; Stephen Y Chan; Sara O Vargas; Elena Arons; Ying-Yi Zhang; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2014-04-28       Impact factor: 29.690

5.  Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.

Authors:  Bradley A Maron; Alexander R Opotowsky; Michael J Landzberg; Joseph Loscalzo; Aaron B Waxman; Jane A Leopold
Journal:  Eur J Heart Fail       Date:  2012-10-30       Impact factor: 15.534

6.  Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).

Authors:  Bradley A Maron; Aaron B Waxman; Alexander R Opotowsky; Hunter Gillies; Christiana Blair; Reza Aghamohammadzadeh; Joseph Loscalzo; Jane A Leopold
Journal:  Am J Cardiol       Date:  2013-06-07       Impact factor: 2.778

7.  Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Authors:  David Langleben; Stylianos Orfanos
Journal:  Pulm Circ       Date:  2017-06-20       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.